Several novel drug treatments targeting specific pathways involved in EoE development are being investigated, including anti-interleukin (IL)-4, IL-13, and IL-5 monoclonal antibodies and thymic stromal lymphopoietin (TSLP) inhibitor signaling pathways [36]. This evidence concerns the gene TSLP and eosinophilic esophagitis.